The U.S. Food and Drug Administration (FDA) has granted fast track designation to pegunigalsidase alfa, or PRX-102, Protalix BioTherapeutics’ therapy candidate under development for Fabry disease. FDA’s fast track status is designed to facilitate the development and speed up FDA review of investigational drugs and vaccines for serious conditions…
News
Two-year data from Protalix BioTherapeutics’ Phase 1/2 extension trial of PRX-102 (pegunigalsidase alfa) show that the treatment prevented a decline in kidney and heart function in Fabry disease patients. People in this small, open-label study also reported a significant reduction in the severity of their symptoms. The data support…
The European Commission has granted Protalix BioTherapeutics’ experimental treatment PRX-102 (pegunigalsidase alfa) Orphan Drug Designation for the treatment of Fabry disease, the company recently announced. The decision follows a European Medicines Agency (EMA) recommendation in November 2017, which stated the therapy may be of “significant benefit” to Fabry…
Amicus Therapeutics recently submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational oral medicine migalastat for treatment of patients 16 years and older with Fabry disease who have so-called “amenable” mutations. The NDA seeks migalastat’s approval in the U.S. as an alternative to intravenous enzyme…
Recent Posts
- Eye tests reveal possible early signs of Fabry disease in two sisters
- US developer gets rights to potential Fabry drug in deal worth up to $475M
- Film explores how to find joy amid suffering and hope within despair
- Phase 3 trial launches to evaluate new treatment for Fabry disease
- Long-term therapy stabilizes eye health in Fabry disease, study finds